MoonLake Immunotherapeutics (MLTX) Income from Continuing Operations (2021 - 2026)
MoonLake Immunotherapeutics' (MLTX) quarterly Income from Continuing Operations came in at 69707000.0 in Q1 2026, down 71.87% year-on-year from 247764982.3 in Q1 2025, and down 10.61% quarter-over-quarter from 63018000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 69707000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 71.87% year-over-year to 69707000.0 in Q1 2026; TTM through Mar 2026 was 259470000.0, a 75.52% decrease from a year earlier, with the FY2025 full-year figure at 230321000.0, down 89.96% from the prior year.
- Income from Continuing Operations eased to 69707000.0 in Q1 2026 per MLTX's latest filing, from 63018000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7887273.0 in Q4 2023 and bottomed at 70694000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 17416329.0 (2022), against an average of 31168061.71.
- Biggest YoY gain for Income from Continuing Operations was 69.3% in 2022; the steepest drop was 20715.22% in 2022.
- Year by year, Income from Continuing Operations stood at 16467930.0 in 2022, then jumped by 52.11% to 7887273.0 in 2023, then tumbled by 488.23% to 46395000.0 in 2024, then plunged by 35.83% to 63018000.0 in 2025, then retreated by 10.61% to 69707000.0 in 2026.
- Per Business Quant, the three latest MLTX Income from Continuing Operations figures stand at 69707000.0 (Q1 2026), 63018000.0 (Q4 2025), and 70694000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | -69.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.71 Mn |
| Dec 31, 2025 | -63.02 Mn |
| Sep 30, 2025 | -70.69 Mn |
| Jun 30, 2025 | -56.05 Mn |
| Mar 31, 2025 | -40.56 Mn |
| Dec 31, 2024 | -46.40 Mn |
| Sep 30, 2024 | -36.11 Mn |
| Jun 30, 2024 | -24.76 Mn |
| Mar 31, 2024 | -13.98 Mn |
| Dec 31, 2023 | -7.89 Mn |
| Sep 30, 2023 | -11.62 Mn |
| Jun 30, 2023 | -12.35 Mn |
| Mar 31, 2023 | -12.22 Mn |
| Dec 31, 2022 | -16.47 Mn |
| Sep 30, 2022 | -14.74 Mn |
| Jun 30, 2022 | -17.42 Mn |
| Mar 31, 2022 | -15.88 Mn |
| Dec 31, 2021 | -53.64 Mn |
| Sep 30, 2021 | -6.29 Mn |
| Jun 30, 2021 | -32.69 Mn |